| Literature DB >> 34583775 |
Ines Pauwels1, Ann Versporten2, Helene Vermeulen3, Erika Vlieghe4,5, Herman Goossens2.
Abstract
BACKGROUND: The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS) provides a methodology to support hospitals worldwide in collecting antimicrobial use data. We aim to evaluate the impact of the Global-PPS on local antimicrobial stewardship (AMS) programmes and assess health care professionals' educational needs and barriers for implementing AMS.Entities:
Keywords: Antimicrobial stewardship; Hospital; Point prevalence survey
Mesh:
Substances:
Year: 2021 PMID: 34583775 PMCID: PMC8478001 DOI: 10.1186/s13756-021-01010-w
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Overview of countries participating in the antimicrobial stewardship survey
Hospital characteristics
| n (%) | |||
|---|---|---|---|
| Hospitals that conducted PPS (n = 192) | Hospitals planning to conduct PPS (n = 56) | Total number of hospitals (n = 248) | |
| Tertiary hospital | 134 (69.8) | 29 (51.8) | 163 (65.7) |
| Secondary hospital | 28 (14.6) | 16 (28.6) | 44 (17.7) |
| Paediatric hospital | 12 (6.3) | 1 (1.8) | 13 (5.2) |
| Other specialised hospital | 7 (3.6) | 5 (8.9) | 12 (4.8) |
| Primary care institution | 6 (3.1) | 5 (8.9) | 11 (4.4) |
| Infectious diseases specialised hospital | 5 (2.6) | 0 (0.0) | 5 (2.0) |
| Yes | 153 (79.7) | 44 (78.6) | 197 (79.4) |
| No | 39 (20.3) | 12 (21.4) | 51 (20.6) |
| Less than 100 | 20 (10.4) | 8 (14.3) | 28 (11.3) |
| 101–250 | 43 (22.4) | 14 (25.0) | 57 (23.0) |
| 251–500 | 59 (30.7) | 17 (30.4) | 76 (30.6) |
| 501–1000 | 43 (22.4) | 10 (17.9) | 53 (21.4) |
| 1001–2000 | 20 (10.4) | 5 (8.9) | 25 (10.1) |
| More than 2000 | 7 (3.6) | 2 (3.6) | 9 (3.6) |
*Tertiary hospital: clinical services are highly differentiated by function. Provides regional services and regularly takes referrals from other (primary and secondary) hospitals. Secondary hospital: clinical services are highly differentiated by function. Takes some referrals from other (primary) hospitals. Primary care institution: has only few medical specialties. Only limited laboratory services are available. Infectious diseases specialised hospital and paediatric hospital: single clinical specialty, possibly with sub-specialties. Highly specialised staff and technical equipment [25]. **Inpatient beds: accommodate hospitalized patients who stay in the hospital for a minimum of one night
Fig. 2Problems related to antimicrobial prescribing as identified from Global-PPS results (% of hospitals). *Perioperative antibiotics for prevention of surgical site infections, administered for a period > 24 h
Hospital AMS structures and activities, overall and by region
| n (%) | n/n (%) | ||||||
|---|---|---|---|---|---|---|---|
| Africa (n = 38) | Asia (n = 91) | Europe (n = 61) | Latin America (n = 31) | Northern America (n = 24) | Total (n = 248) | Initiated as a result of PPS findings* | |
| Local, evidence-based guidelines | 12 (31.6) | 69 (75.8) | 44 (72.1) | 24 (77.4) | 23 (95.8) | 175 (70.6) | 67/143 (46.9) |
| Antimicrobial formulary | 9 (23.7) | 68 (74.7) | 41 (67.2) | 14 (45.2) | 21 (87.5) | 156 (62.9) | 42/126 (33.3) |
| Education and communication | 15 (39.5) | 38 (41.8) | 40 (65.6) | 19 (61.3) | 16 (66.7) | 129 (52.0) | 50/98 (51.0) |
| AMS committee** | 12 (31.6) | 46 (50.5) | 27 (44.3) | 16 (51.6) | 23 (95.8) | 127 (51.2) | 34/102 (33.3) |
| AMS team† | 8 (21.1) | 42 (46.2) | 31( 50.8) | 16 (51.6) | 19 (79.2) | 119 (48.0) | 27/95 (28.4) |
| Specific AMS interventions†† | 7 (18.4) | 31 (34.1) | 24 (39.3) | 11 (35.5) | 23 (95.8) | 99 (39.9) | 32/81 (39.5) |
| Information technology support | 1 (2.6) | 43 (47.3) | 14 (23.0) | 7 (22.6) | 9 (37.5) | 76 (30.6) | 25/62 (40.3) |
| Other AMS activities | 1 (2.6) | 3 (3.3) | 2 (3.3) | 2 (6.5) | 2 (8.3) | 10 (4.0) | |
| No AMS activities | 11 (28.9) | 6 (6.6) | 1 (1.6) | 2 (6.5) | 0 (0.0) | 20 (8.1) | |
Results for Oceania (n = 3) are not reported separately
*For the group of hospitals participating in the Global-PPS and with the respective AMS component implemented in the hospital
**The organizational structure responsible for defining the antimicrobial stewardship strategy [12]
†The core operational team, responsible for the implementation of the antimicrobial stewardship activities in daily practice [12]
††E.g. audit and feedback, automatic stop orders, intravenous-to-oral switch policies etc.…
Learning needs of hospitals on AMS
| n (%) | ||||
|---|---|---|---|---|
| High-income countries (n = 76) | Low- and middle-income countries (n = 156) | Total (n = 232) | ||
| Optimising therapeutic antimicrobial use | 43 (56.6) | 105 (67.3) | 148 (63.8) | 0.147 |
| Optimising surgical prophylaxis | 38 (50.0) | 91 (58.3) | 129 (55.6) | 0.290 |
| Translating PPS results into AMS interventions | 38 (50.0) | 71 (45.5) | 109 (47.0) | 0.615 |
| Communicating with prescribers | 35 (46.1) | 61 (39.1) | 96 (41.4) | 0.386 |
| Managing difficult-to-treat MDRO infections* | 25 (32.9) | 71 (45.5) | 96 (41.4) | 0.091 |
| Identifying the low-hanging fruit for AMS in the hospital | 38 (50.0) | 56 (35.9) | 94 (40.5) | 0.056 |
| Translating PPS results into IPC** interventions | 17 (22.4) | 61 (39.1) | 78 (33.6) | 0.017 |
| Formulating/revising guidelines | 21 (27.6) | 54 (34.6) | 75 (32.3) | 0.359 |
| Performing audit and feedback | 17 (22.4) | 54 (34.6) | 71 (30.6) | 0.081 |
| Understanding antimicrobial susceptibility data | 15 (19.7) | 55 (35.3) | 70 (30.2) | 0.024 |
| How to create an active stewardship committee/team | 9 (11.8) | 41 (26.3) | 50 (21.6) | 0.019 |
| How to communicate with patients on antimicrobial use | 13 (17.1) | 28 (18.0) | 41 (17.7) | 1.000 |
| Other learning needs | 1 (1.3) | 2 (1.3) | 3 (1.3) | 1.000 |
| None | 2 (2.6) | 0 (0.0) | 2 (0.9) | 0.106 |
*MDRO: multi-drug resistant organisms; **IPC: infection prevention and control †Statistical significance evaluated using the Pearson’s chi-squared test or Fisher’s exact test. Significance level (α) has been corrected for multiple testing
Barriers to implementation of AMS
| n (%) | ||||
|---|---|---|---|---|
| High-income countries (n = 80) | Low- and middle-income countries (n = 163) | Total (n = 243) | ||
| Lack of time to perform AMS activities | 50 (62.5) | 78 (47.9) | 128 (52.7) | 0.044 |
| Lack of knowledge on good prescribing practices | 28 (35.0) | 74 (45.4) | 102 (42.0) | 0.160 |
| Lack of funding for AMS programme | 41 (51.3) | 56 (34.4) | 97 (39.9) | 0.017 |
| Lack of cooperation from prescribers | 21 (26.3) | 67 (41.1) | 88 (36.2) | 0.034 |
| Lack of information technology | 37 (46.3) | 36 (22.1) | 73 (30.0) | |
| Unavailability of prescribing guidelines | 6 (7.5) | 58 (35.6) | 64 (26.3) | |
| Lack of qualified personnel | 13 (16.3) | 44 (27.0) | 57 (23.5) | 0.090 |
| Lack of support from hospital management | 14 (17.5) | 40 (24.5) | 54 (22.2) | 0.282 |
| Insufficient laboratory capacity | 10 (12.5) | 57 (35.0) | 54 (22.2) | |
| Lack of expertise/training within the AMS team | 13 (16.3) | 32 (19.6) | 45 (18.5) | 0.644 |
| Suboptimal use of laboratory services | 2 (2.5) | 35 (21.5) | 37 (15.2) | |
| Lack of confidence in the hospital's IPC** processes | 4 (5.0) | 29 (17.8) | 33 (13.6) | 0.011 |
| Lack of trust in prescribing guidelines | 7 (8.8) | 23 (14.1) | 30 (12.4) | 0.324 |
| Regular shortages/stock outs of essential antibiotics | 4 (5.0) | 24 (14.7) | 28 (11.5) | 0.044 |
| Patient demands | 7 (8.8) | 18 (11.0) | 25 (10.3) | 0.743 |
| Poor quality of antibiotics | 0 (0.0) | 15 (9.2) | 15 (6.2) | 0.003 |
| High cost of antibiotics | 0 (0.0) | 15 (9.2) | 15 (6.2) | 0.003 |
| No barriers | 5 (6.3) | 1 (0.6) | 6 (2.5) | 0.016 |
*Statistical significance evaluated using the Pearson’s chi-squared test or Fisher’s exact test. Significance level (α) has been corrected for multiple testing. **Infection prevention and control
Values in boldface indicate statistical significance